News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

29

Neurolens Top 30 Healthcare Company on Inc. 5000 2022 List

28th fastest-growing healthcare company on 2022 list Ranked #1,773 overall among America’s fastest-growing private...

9

Neurolenses Have Significant Impact on Reading Speed

New parallel arm study results have implications for productivity and learning Coppell, Texas, August 8,...

4

Exagen Inc. Reports Second Quarter 2022 Results

Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters SAN DIEGO, Aug. 04, 2022 (GLOBE...

4

ATEC Reports Second Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

Total revenue grows 35% to $84 million, including organic revenue growth of 30% EOS...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

4

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

TIGER study to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

7

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome

Study to be initiated with Mayo Clinic’s Post-COVID Care Clinic subjects ROCKAWAY, N.J., July 07,...

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

AVISE® Lupus more clinically effective than current standard of care SAN DIEGO, July 05, 2022 (GLOBE...

22

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

PERIO-1 and PERIO-2 studies evaluating integration of SD-101 and PEDD administration DENVER and CHICAGO,...

9

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...